PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 183 products for "PD-1/PD-L1".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.14 kDa (Predicted)Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purity:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Color and Shape:LiquidMolecular weight:143.78 kDa (Predicted)Zimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purity:95%Color and Shape:Transparent LiquidMolecular weight:146.54 kDa (Predicted)AUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purity:95.07% - 99.29%Color and Shape:White SolidMolecular weight:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purity:97.2% (SDS-PAGE); 95.3% (SEC-HPLC) - 97.7% (SDS-PAGE); 99.59% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:146.03 kDa (Predicted)BMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.115Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.72 kDa (Predicted)Dostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:144.18 kDa (Predicted)Tislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purity:95.07%Color and Shape:Transparent LiquidMolecular weight:145 kDa (Predicted)Ezabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.21 kDa (Predicted)Spartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:Transparent LiquidMolecular weight:145.74 kDa (Predicted)Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurity:98%Color and Shape:SolidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purity:99.92%Color and Shape:SolidMolecular weight:348.4382Eciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPurity:98%Color and Shape:SolidIparomlimab
CAS:Iparomlimab serves as a functional therapeutic tool specifically designed to enable the precise detection and neutralization of the PD-1 protein which plays a pivotal role in the induction of peripheral tolerance and tumor immune evasion during strictly monitored laboratory observation periods and molecular investigations to evaluate the pharmacological potential of targeted checkpoint inhibition in specialized preclinical research environments to facilitate the study of cancer immunotherapies.Purity:95%Color and Shape:Transparent LiquidMolecular weight:146.70 kDa (Predicted)MS1-96
MS1-96 is an orally active PD-L1 (programmed death-ligand 1) degrader. It effectively reduces PD-L1 protein expression levels in various colorectal cancer (CRC) cell lines. The compound loses its ability to induce PD-L1 degradation upon HIP1R knockdown. MS1-96 binds directly to PD-L1 (KD= 2.58 μM) and enhances the interaction between HIP1R and PD-L1, altering PD-L1's intracellular transport in clathrin-coated vesicles. Additionally, MS1-96 induces abnormal N-glycosylation of PD-L1, leading to protein instability and accelerated lysosome-mediated degradation. MS1-96 is applicable for colorectal cancer research.PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Color and Shape:Odour SolidTPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Color and Shape:SolidMolecular weight:2602.69HLX43
HLX43 is an ADC targeting PD-L1 with DAR=8 and a cleavable linker that releases C24, possessing both immune blockade and bystander killing effects.Purity:95% - 98.30% (SEC-HPLC)Molecular weight:153.06 kDa (Predicted)Human PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Color and Shape:SolidMolecular weight:2350.576
